Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences published dual small-molecule-controlled genome editing systems that keep CRISPR largely silent until drug induction. In a Science Translational Medicine study, the team described PRINCE and Little Prince, designed to switch editing on with inducers and reduce background activity when the inducer is absent. The approach centers on engineering CRISPR activity to respond to orally or otherwise deliverable small molecules, which is meant to improve temporal control in vivo. “Little Prince” and PRINCE are positioned as dual systems intended to balance on-demand editing with tight off-state performance in living tissues. The work targets a key translational barrier for CRISPR therapeutics—managing safety by limiting unintended genome modification outside the intended treatment window.